Aldo-Keto Reductase Family 1 Member C3

Aldo-keto reductase that functions as a bi-directional 17 BETA, 20 ALPHA-HYDROXYSTEROID DEHYDROGENASE. It catalyzes the reduction of PROSTAGLANDIN D2 and PROSTAGLANDIN H2, as well as the oxidation of 9alpha,11beta-PGF2 to prostaglandin D2. It can also interconvert estrogens, ANDROGENS; and PROGESTINS between their active forms and inactive metabolites.

Also Known As:

Networked: 29 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Li, Jing: 2 articles (07/2016 - 02/2014)
2.	Li, Yi: 2 articles (07/2016 - 02/2014)
3.	Tian, Yuantong: 2 articles (07/2016 - 02/2014)
4.	Zhang, Haitao: 2 articles (07/2016 - 02/2014)
5.	Zhao, Lijing: 2 articles (07/2016 - 02/2014)
6.	Zhao, Xuejian: 2 articles (07/2016 - 02/2014)
7.	Brame, Lacy S: 2 articles (01/2013 - 01/2012)
8.	Fung, Kar-Ming: 2 articles (01/2013 - 01/2012)
9.	Lin, Hsueh-Kung: 2 articles (01/2013 - 01/2012)
10.	Yang, Qing: 2 articles (01/2013 - 01/2012)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 07/01/2016 - "Aldo-keto reductase family 1 member C3 has recently been regarded as a potential therapeutic target in castrate-resistant prostate cancer. " 02/24/2023 - "Aldo-keto reductase family 1 member C3 (AKR1C3) plays an important role in prostate cancer (PCa) progression, particularly in castration-resistant prostate cancer (CRPC). " 11/03/2022 - "Aldo-keto reductase family 1 member C3 (AKR1C3) is important in prostate cancer progression, being a potential biomarker in metastatic castration-resistant prostate cancer (mCRPC). " 08/02/2016 - "Quality of life effects of androgen deprivation therapy in a prostate cancer cohort in New Zealand: can we minimize effects using a stratification based on the aldo-keto reductase family 1, member C3 rs12529 gene polymorphism?" 02/26/2014 - "Aldo-keto reductase family 1 member C3 (AKR1C3) is a key steroidogenic enzyme that is overexpressed in prostate cancer (PCa) and is associated with the development of castration-resistant prostate cancer (CRPC). "
2.	Neoplasms (Cancer) 04/01/2016 - "Lower levels of AKR1C3 transcript were observed in diffuse and intestinal types of GC, whereas AKR1C3 protein levels were decreased in tumors with multisite localization, in diffuse histological type, T3, T4, and G3 grades. " 02/01/2014 - "Over-expression of the aldo-keto reductase family 1 member C3 (AKR1C3) has been demonstrated in many human cancers. " 09/01/2011 - "Levels of AKR1C3 protein did not correlate with tumor responsiveness. " 04/01/2008 - "The expression scores for AR, 5alpha-reductase type 1 (SRD5A1), 5alpha-reductase type 2 (SRD5A2), and aldo-keto reductase family 1 member C3 (AKR1C3) in the metastatic lesion of stage IV or recurrent cancer (n = 6) were 284.2 (30.1), 300 (0.0), 279.2 (51) and 254.2 (74.9), respectively; these scores were significantly higher than the respective scores of 121.8 (82.1), 135.1 (59.7), 167.0 (66.4) and 150.5 (62.8) for stage II and III cancer (n = 54) (p<0.001, p<0.001, p = 0.002 and p = 0.018, respectively). " 12/11/2020 - "Over the last few years, aldo-keto reductase family 1 member C3 (AKR1C3) has been associated with the emergence of multidrug resistance (MDR), thereby hindering chemotherapy against cancer. "
3.	Adenocarcinoma 01/01/2013 - "Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung." 01/01/2012 - "Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma."
4.	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/01/2013 - "Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung."
5.	Small Cell Carcinoma 01/01/2012 - "Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma."

Related Drugs and Biologics

1.	Enzymes
2.	Androgens
3.	abiraterone
4.	Biomarkers (Surrogate Marker)
5.	Testosterone (Sustanon)
6.	Proteins (Proteins, Gene)
7.	Peroxiredoxins
8.	Resistin
9.	Calcium-Sensing Receptors
10.	NG-Nitroarginine Methyl Ester (L-NAME)

Related Therapies and Procedures

1.	Castration
2.	Therapeutics
3.	Drug Therapy (Chemotherapy)